mRNA vaccines still lead the COVID-19 pack: Data Byte
Sinovac’s Phase III data ranks vaccine lowest in protection rate
mRNA vaccines were the first to be authorized, and pivotal data show them to still be the most effective as a sixth COVID-19 vaccine reads out.
Brazil’s Butantan Institute, which led Phase III testing of CoronaVac, said Tuesday that the inactivated SARS-CoV-2 vaccine from China’s Sinovac Biotech Ltd. (NASDAQ:SVA) had an overall efficacy of 50.3% in Phase III testing.
That rate falls short of the other COVID-19 vaccines that have reported Phase III data. Among 9,200 subjects there were 252 cases of very mild COVID, 85 in the vaccine group and 167 in the placebo group.